13 research outputs found
Factors associated with ART initiation during pre-ART follow-up in HIV-infected children (<i>n =</i> 135,479) in the IeDEA Global Cohort Consortium, 2004–2015.
<p>Factors associated with ART initiation during pre-ART follow-up in HIV-infected children (<i>n =</i> 135,479) in the IeDEA Global Cohort Consortium, 2004–2015.</p
ART initiation after 24 months of follow-up according to eligibility at last contact, by region, among the 135,479 HIV-infected children (including those lost to follow-up or deceased prior to ART initiation) in the IeDEA Global Cohort Consortium, 2004–2015.
<p>ART initiation after 24 months of follow-up according to eligibility at last contact, by region, among the 135,479 HIV-infected children (including those lost to follow-up or deceased prior to ART initiation) in the IeDEA Global Cohort Consortium, 2004–2015.</p
Crude and adjusted hazard ratios (HR) with 95% confidence intervals (CI) of risk of death or loss-to-follow-up of adolescents after ART initiation (n = 650).
<p>Pediatric IeDEA West Africa Collaboration.</p><p>All analyses used the center as a cluster variable, taking into account the correlation of the observations within a same center.</p><p>HR: Hazard ratio.</p><p>aHR: adjusted hazard ratio.</p><p>MD: missing data.</p><p>ART: Antiretroviral therapy.</p><p>NNRTI: non nucleoside reverse transcriptase inhibitor.</p><p>Severe anemia: haemoglobin≤6.9 g/dL.</p><p>Severe immunosuppression : CD4<200 cells/mm<sup>3</sup>.</p
Baseline (HIV diagnosis or, if unavailable, enrollment in care) characteristics of the 135,479 HIV-infected children included, by region, in the IeDEA Global Cohort Consortium, 2004–2015.
<p>Baseline (HIV diagnosis or, if unavailable, enrollment in care) characteristics of the 135,479 HIV-infected children included, by region, in the IeDEA Global Cohort Consortium, 2004–2015.</p
Probability of retention in HIV care while on antiretroviral therapy (ART) according to disclosed HIV status taking into account the delayed entry at age of 10 years (n = 650).
<p>Pediatric IeDEA West Africa Collaboration. * Estimation at 36 months from ART initiation.</p
Characteristics of adolescents at HIV disclosure or last contact.
<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>N: number.</p
Characteristics of the process of HIV disclosure of adolescents.
<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>ART: Antiretroviral therapy.</p>*<p>Consisted in other persons of the family (uncle, aunt, grand-mother, grand-father, adoptive father or mother), persons from foster care shelters or NGOs (n = 14), nobody involved because of reading the notice (n = 4).</p
Cohort profile for the adolescent HIV disclosure study.
<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p
Characteristics of adolescents at ART initiation.
<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>ART: Antiretroviral treatment; NNRTI: non nucleoside reverse transcriptase inhibitor;</p><p>N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.</p
Flow diagram of the inclusion criteria of the 135,479 HIV-infected children aged 0–19 years enrolled in the IeDEA Global Cohort Consortium from 2004 to 2015.
<p>Flow diagram of the inclusion criteria of the 135,479 HIV-infected children aged 0–19 years enrolled in the IeDEA Global Cohort Consortium from 2004 to 2015.</p